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Precis: Flushing postmenopausal women appear to have better vascular responses than non-flushing 
women but paradoxically, such women appear to have worse (not better) CVD risk factors. 
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ABSTRACT 
Background: 70% of postmenopausal women suffer from hot flushes causing significant morbidity in 
25%. Oestrogen replacement provides symptom relief, but its use has declined following safety issues 
and there is, as yet, no good alternative.  Pathophysiology is poorly understood, but one proposed 
mechanism is altered peripheral vascular reactivity. It has recently been suggested that the presence of 
flushing may be a marker of underlying cardiovascular risk. 
Aim: To measure i) peripheral vascular reactivity in subcutaneous vessels ii) routine and novel 
cardiovascular risk factors in postmenopausal women who flush, and compare results to a matched 
group of women who do not flush. 
Methods: 32 postmenopausal women with at least 20 flushes/week and 14 non-flushing 
postmenopausal women were recruited.  Cutaneous microvascular perfusion was measured using laser 
Doppler imaging and endothelial function was assessed by iontophoresis (administration of vasoactive 
agents through the skin by an electric current) of acetylcholine [Ach] (endothelial-dependent) and 
sodium nitroprusside [SNP] (endothelial independent).  Blood samples for risk factors were taken 
following vascular assessment. 
Results: Both study groups were well matched demographically. The response of the subcutaneous 
vessels was greater in women who flushed than those who did not, following administration of both 
the endothelium-dependent and independent vasodilators, (ACh, p = < 0.001, SNP, p = 0.001, 2-way 
ANOVA).  By contrast, levels of HDL-cholesterol and ApoA1 were significantly lower in the flushing 
women compared with the control women (P=0.02 and 0.002, respectively), and levels of inter-
cellular adhesion molecule-1 (ICAM-1) were higher (P=0.03), findings robust to adjustment for 
confounders, suggesting an adverse cardiovascular risk profile. 
Conclusion: These results confirm a better vascular response in women but paradoxically, such 
women appear to have worse (not better) CVD risk factors in particular l lower HDL-cholesterol but 
also higher non-HDL-c to HDL-c ratio and increased ICAM-1.  Further studies are needed to assess 
vascular risk factors in women who flush. 
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INTRODUCTION 
The menopause is defined by the World Health Organisation (WHO) as the permanent cessation of 
menstrual periods that occurs naturally, or is induced by surgery, chemotherapy, or radiation. The 
climacteric is the period of transition from regular menstruation to its cessation, and during this time 
gonadal hormones change substantially. 
There are a number of symptoms associated with this period and decreasing oestrogen levels, although 
some women will experience none of these.  They include hot flushes and night sweats (vasomotor 
symptoms), vaginal symptoms, depression, anxiety, irritability and mood swings (psychological 
effects), joint pains, migraines or headaches, sleeping problems and urinary incontinence. 
Hot flushes are the most commonly reported symptom, occurring in approximately 70% of women (1) 
causing significant morbidity in 25%, affecting social life and even the ability to work (2).  They are 
periods of intense heat, which are associated with sweating and peripheral vasodilation.  Flushing 
commonly occurs when hypooestrogenism follows a period of oestrogen exposure.  If left untreated, 
hot flushes resolve within one year, or less, in the majority of postmenopausal women.  However, a 
third will report symptoms that last up to 5 years after natural menopause, and in 20% hot flushes 
persist for up to 15 years (3). 
Hot flushes and other related symptoms have been successfully treated with oestrogen for years, 
effective in over 80% of cases.  In 1995, 37% of American women took HRT, principally for this 
purpose.  For this reason few studies were carried out investigating the pathophysiology of flushes.  
However, following publication of results from studies such as the Women’s Health Initiative and 
Million Women Study there has been renewed interest in this topic since hormone replacement 
therapy (HRT) prescription dropped 50%. 
The mechanism of flushing is still poorly understood, although hypotheses now exist surrounding both 
central and peripheral mechanisms. 
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It has been shown that postmenopausal women who flush have a diminished vasoconstrictor response 
to cold (4) and that they have increased blood flow to the forearm and hand during a flushing episode 
(5)  This altered (potentially heightened) peripheral vascular reactivity is another proposed mechanism 
responsible for the pathophysiology underlying hot flushes.  In this study, we aimed to assess vascular 
function in postmenopausal women who flush and compare it with postmenopausal women who do 
not flush.   
In addition we aimed to study factors which might influence vascular reactivity, and to examine 
associations between hot flushes and endothelial function and several circulating cardiovascular 
disease (CVD) risk factors.  These included lipids and apolipoproteins, inflammatory markers and 
intracellular adhesion molecule-1 (ICAM-1), the latter being linked to vascular dysfunction and higher 
risk of CVD and especially diabetes in several studies (6). 
MATERIALS AND METHODS 
Study Participants 
A total of 32 postmenopausal women who each experienced at least 20 flushes/day and 14 non-
flushing women were recruited to participate in this study.  Recruitment of volunteers was facilitated 
by Scottish media coverage as well as taking place within relevant out-patient clinics.  A number of 
women (cases and controls) were also recruited from the West of Scotland Breast Screening Centre in 
Glasgow. 
Participating women were all aged 50-65 years, non-smokers, not known to be hypertensive, non-
diabetic and not taking any drugs which could affect vascular function.  These strict recruitment 
criteria minimised potential for confounding by several common factors. Menopausal status was 
determined by either an FSH greater than 20 Units/Litre or amenorrhoea for 1 year or longer.   
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Design and Procedures 
All study participants were assessed using Laser Doppler Imaging (LDI) with iontophoresis of 
vasoactive compounds.  Blood was obtained at the time of LDI assessment.  Each participant in the 
flushing group was requested to keep a ‘Hot Flush’ diary for 4 weeks prior to assessment. 
All work was performed according to the Declaration of Helsinki with approval granted by the 
institutional ethics committee (REC 01/50704/43).  All patients gave written informed consent. 
LASER DOPPLER IMAGING WITH IONTOPHORESIS 
Non-invasive skin perfusion can be measured using Laser Doppler Iontophoresis (LDI) (7). 
Iontophoresis is a technique which allows for transdermal delivery of vasodilator agents acetylcholine 
(ACh) and sodium nitroprusside (SNP) across the skin under the influence of an applied current.  In 
the past iontophoresis has been used in conjunction with laser Doppler flowmetry, a non-invasive 
method for assessing microvascular perfusion at a single point (8).  More-recently, iontophoresis has 
been combined with laser Doppler imaging, which reduces measurement variability (9-10). This is 
because unlike laser Doppler flowmetry, laser Doppler imaging measures perfusion across many 
points (11), and an average measure of perfusion can be computed for any chosen area. 
Iontophoresis of acetylcholine (ACh) at the anode tests endothelial function since its vasodilator action 
involves binding to muscarinic receptors on endothelial cells, with subsequent generation of NO. It is 
therefore said to be ‘endothelium dependent’. Vasodilatation is ultimately mediated by action of NO 
on vascular smooth muscle (via the cGMP pathway) and so iontophoresis of an NO donor, sodium 
nitroprusside (SNP), delivered at the cathode, is used as an ‘endothelium-independent’ control to test 
the integrity of vascular smooth muscle. 
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Drug delivery is achieved using a battery-powered constant-current iontophoresis controller (MIC-1e; 
Moor Instruments Ltd., Axminster, U.K.).  The chambers used for iontophoresis (ION 6; Moor 
Instruments Ltd.) are constructed of Perspex (internal diameter 22mm; area 3.8cm2) with an internal 
platinum wire electrode.  Two chambers are attached to the skin of the volar aspect of the forearm by 
means of double-sided adhesive discs, avoiding hair, broken skin, and superficial veins.  The chambers 
are connected to the anode and cathode connections on the iontophoresis controller and the voltage 
across the chambers is monitored.  A thermometer is also attached to the arm in order to measure skin 
temperature. 
2.5ml of 1% ACh (Sigma) is introduced to the anodal chamber and 2.5ml of 1% SNP (Sigma) is 
introduced to the cathodal chamber.  The vehicle for these drugs is 0.5% sodium chloride (NaCl).  
Both of these agents are delivered simultaneously during each period of current administration.  Fluid 
is prevented from escaping by placing circular 32mm coverslips over the chambers. 
The iontophoresis protocol involves incremental current delivery with four scans at 5µA, four at 
10µA, four at 15µA and two at 20µA, giving a total charge of 8mC. 
The laser doppler imager (Moor Instruments, UK) is equipped with a red laser (wavelength 633nm, 
power 1mW, beam diameter 1mm).  The laser is scanned in a raster fashion over both chambers and 
through the coverslips.  The backscattered light is collected by photodetectors and converted into a 
signal proportional to perfusion in arbitrary perfusion (flux) units (PU) that is displayed as a colour-
coded image on a monitor.  Perfusion measurements are obtained using the imager manufacturer’s 
image analysis software by outlining a region of interest (ROI) around the internal circumference of 
the chamber.  Statistical analysis of the ROI is subsequently performed to yield the median flux value 
across approximately 700 measurement points.  Twenty repetitive scans are taken during each LDI 
assessment, the first being a control (before current administration), followed by the incremental 
current protocol as described above (fourteen scans), and followed by a further five scans with no 
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current administration.  An assessment of the overall response to the drugs is obtained by calculating 
the area under the curve (AUC). 
This technique is reproducible with between-day and within-day coefficients of variation of 6.4 ±33% 
and 8.9 ±5.3% respectively.  Variability being reduced by averaging perfusion over a large skin area 
(12). 
All participants fasted for at least 5 hours prior to assessment (water only permitted).  Prior to the 
procedure, patients were allowed to acclimatize for 15 minutes in a temperature-controlled room.  
Participants all lie in a semi-recumbent position with the flexor aspect of the forearm exposed on an 
arm rest. 
 
Figure 1: Image of laser Doppler iontophoresis equipment. 
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PLASMA ANALYSIS 
At LDI assessment, blood was collected and processed to allow measurements of insulin, glucose, 
lipids, apolipoproteins, CRP, and ICAM-1.   
Samples were spun in the centrifuge at 3000rpm, at 4οC for 10 minutes.  The plasma was stored at -
80οC in 1ml aliquots, within 1 hour of being taken from the patient. 
STATISTICAL ANALYSIS 
Measurement of vascular responses was performed using raw values.  Comparisons were by General 
Linear Model.  Because of the marked differences in variances between basal perfusion values and the 
maximal responses to the drugs, but the similar coefficients of variation, log10 transformation of the 
data was performed to equalise the variances and thereby permit parametric data analysis. 
Log10 transformation of the plasma data was also performed to allow for parametric data analysis with 
comparison by students t-test.  In addition, plasma data was adjusted for BMI, Age, Years since last 
menstrual period (LMP) and Parity using general linear model. 
Comparison of demographic data was by t-test as data were of a Gaussian distribution.  
RESULTS 
32 women with severe hot flushing and 14 women with no hot flushing, aged between 50 and 65, who 
were medically fit and were not taking drugs that might impact on vascular reactivity, were recruited 
and had LDI assessment of vascular reactivity of the subcutaneous vessels.   
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A full set of demographic characteristics were available for 29 flushing women and 13 control women, 
and they were broadly matched, but even so we were careful to adjust CVD risk factor comparisons 
for age, BMI, parity and time since LMP. (Table 1) 
Responses to acetylcholine (ACh) and sodium nitroprusside (SNP) 
Vascular reactivity for 32 flushers and 14 controls (non-flushers) was measured using LDI.  Data was 
analysed as described above.  
The response of the subcutaneous vessels was greater in women who flushed than in those who did not 
(Figure 2).  The enhanced vascular response occurred following administration of both the 
endothelium-dependent (ACh) and independent vasodilators (SNP), (ACh, p = < 0.001, SNP, p = 
0.001, 2-way ANOVA). 
As both groups appeared to show a consistent difference between ACh and SNP responses, this 
difference was calculated and the analysis between groups repeated (using the general linear model).  
However, this calculated difference between the endothelium dependent and independent responses 
was not found to differ between flushers and controls (P=0.17; Figure 3) 
CVD risk factors (Table 2) 
Women with flushing had significantly lower HDL-cholesterol levels (P=0.02), lower apolipoprotein 
A1 (P=0.002), and higher I-CAM levels (P=0.03). 
These results were not affected by adjustment for body mass index (BMI), age, years since last 
menstrual period (YSLMP) and parity:  HDL-cholesterol (P=0.007), Apolipoprotein A1 (P<0.001), 
and I-CAM (P=0.05).   
In the control group HDL-cholesterol also correlated with vascular reactivity as measured by AUC for 
the ACh response (P=0.01, R-Sq 48.3%), but not in the flush group (data available on request).  Again, 
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this relationship remained significant when adjusted for body mass index (BMI), age, and waist hip 
ratio (WHR), P=0.035, R-Sq 60.7%. Also, Apo B was inversely related to Ach mediated vascular 
reactivity in the control group (P=0.02, R-Sq 46%, and adjusted P=0.004, R-Sq 80.8%). 
DISCUSSION  
In this group of postmenopausal women, those with severe flushing have a greater vasodilator 
response than those women with no flushing.  This is in keeping with previous studies showing a 
diminished vasoconstrictor response, and increased blood flow during a hot flush (4-5).  The alteration 
to their vascular function seems to be an increased vasodilatory response in comparison with 
asymptomatic women  
This increase has been demonstrated to be present in both the endothelial dependent (ACh) and 
independent (SNP) responses.  We can therefore say that there is an increased response of the vascular 
smooth muscle to the NO donated by SNP compared to asymptomatic postmenopausal women.  
Sodium nitroprusside dissociates in the circulation to release NO, which activates guanylate cyclase in 
vascular smooth muscle and increases intracellular production of cGMP.  cGMP stimulates calcium 
movement from the cytoplasm to the endoplasmic reticulum and reduces calcium available to bind 
with calmodulin. Vascular smooth muscle relaxes and vessels dilate. 
Endothelium dependent responses are also increased this group of flushing women compared with 
non-flushing women as a result of administration of acetylcholine which acts to stimulate NO 
production by endothelial cells, by binding to muscarinic receptors.  However, the endothelial 
produced NO must still act upon vascular smooth muscle to have a response.  Therefore, in order to 
examine the endothelial response in isolation, we must remove the vascular smooth muscle response 
from the equation.  In order to do this, we have analysed the difference in the ACh and SNP response 
and found no variation in the groups.  It is possible, then, that the enhanced response in the flushing 
group, is due purely to an increased vasomotor smooth muscle response. 
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It is also possible that there are other endothelial derived factors activated that may cause vasodilation.  
These include prostacyclins, since administration of aspirin prior to LDI, leads to reduced endothelial 
dependent responses following both oral (13) and intravenous (14) aspirin, although this has not been 
demonstrated by all studies (7, 10), and electrically induced vasodilation.  However, the vehicle 
0.5%NaCl and the chamber size used have been shown to minimise an electrically induced 
hyperaemic response.  Furthermore, application of a local anaesthetic agent in an attempt to eliminate 
the ‘axon reflex’ thought to be a possible cause of electrically induced hyperaemia did diminish this 
response, but also caused vasoconstriction (12), therefore any vasodilatory effects would be 
superimposed upon already vasoconstricted vessels. 
This apparently ‘better’ vascular response in women who flushed excessively may be anticipated to 
suggest a protective phenotype against vascular risk since impaired skin microvascular function has 
been linked to several conditions associated with greater CVD risk to include diabetes (15), maternal 
obesity (16), and hypercholesterolaemia (17) as well CAD itself (18).   However, by contrast, results 
of recent studies suggest the presence of menopausal flushing may be a marker of cardiovascular risk, 
as marked by reduced flow-mediated dilation (brachial artery) and greater aortic calcification in 
flushers in the Women’s Health Across the Nation Heart Study (19).    To examine these issues in 
more details, we therefore examined CVD risk factors in these women.    
Women who flushed in the present study had lower levels of HDL-cholesterol and ApoA1, and higher 
levels of ICAM-1 than asymptomatic women. Recent work from the Emerging Risk Factor 
Collaboration, which represents the more complete lipid-CVD risk analyses performed anywhere, has 
shown that greater non-HDL-cholesterol (or total cholesterol) but lower HDL-cholesterol are strong 
and independent risk factors for vascular disease in both men and women (20) thereby in keeping with 
greater vascular risk over the long term. 
The blood and vascular data therefore appear contradictory, but can they be explained? 
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It could be said that these women have an imbalance between endothelium-derived vasodilators that 
have anti-thrombotic and antimitogenic properties and vasoconstrictors with proatherogenic activity 
(21).  However, greater vasodilatory response is usually considered a sign of vascular health. 
Endothelium-derived NO is now recognised to be an anti-inflammatory and anti-arteriosclerotic 
molecule; mice lacking the endothelial-type NO synthase gene exhibit hypertension and enhanced 
vascular remodelling in response to injury (22).  One possibility is that these postmenopausal flushing 
women are at increased risk of cardiovascular disease compared with their non-flushing counterparts 
and have reduced synthesis of NO as a result of endothelial dysfunction, and as a result of this have 
increased sensitivity to NO and therefore when exposed to NO, have a greater vasodilatory response. 
The study by Bechlioulis and colleagues (23) found that women in the early stages of menopause had 
endothelial dysfunction, but that this was not associated with a change in plaque size, as the carotid 
intima-media thickness was comparable to that in the premenopausal controls.  Perhaps what we are 
seeing with our results is an increased response to NO due to increased sensitivity as a result of longer 
term underlying endothelial dysfunction leading to decreased synthesis. 
And although there appeared to be no endothelial dependent variation between groups when we 
examined the difference in independent and dependent responses, it is possible that the increased 
response that was smooth muscle driven, is superimposed on a background of early endothelial 
dysfunction that will become more apparent with time. 
As with Findings from the Study of Women’s Health Across the Nation Heart Study (19), 
Gambacciani (24) found arterial blood flow was altered only in women with hot flushes.  This too, is 
in support of Bechlioulis (23) as they also demonstrated that severity of flushes was the most 
important independent predictor of endothelial dysfunction.   
However, flow mediated dilation (FMD) is expressed as percentage change meaning that a larger 
percentage change will occur with a small diameter increase in a narrow vessel, than the same increase 
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in a vessel with a higher baseline lumen diameter.  It is possible then that flushers overall had more 
dilated brachial arteries to begin with, which would be consistent with our data. 
Also, it is possible that smaller diameter cutaneous vessels and the vasodilation that has been found to 
be associated with hypooestrogenism (25), cannot be extrapolated to larger vessels like those studied 
in flow mediated dilation. 
And while measures of peripheral vascular function are used as surrogate markers for coronary 
vascular function, there is a paucity of data showing any clear correlation.  This may be as a result of 
the difference in size of vessels studied.  However there is evidence demonstrating that peripheral 
vascular function acts a prognostic tool.  Impaired brachial artery flow mediated dilation predicts 
cardiac events in hypertensive postmenopausal women(26). 
Women with climacteric symptoms have a lower level of plasma antioxidant activity (27), and 
oxidative stress is associated with cardiovascular risk.  Leal also demonstrated that HRT decreases 
oxidative stress in addition to decreasing number of flushes.  A recent review (28) suggested that a 
possible reason for the opposite effects of the beneficial effect of HRT in younger women within the 
first year of use (29) and detrimental effects in women distant to the menopause may be as a result of 
genuinely altered vascular reactivity making them vulnerable to the effects of HRT. 
Although total cholesterol, elevated LDL-C and low HDL-C are well established risk factors for 
cardiovascular disease (CVD), an association with endothelial dysfunction has not been consistently 
demonstrated. It is also possible that there is an uncoupling of central and peripheral control, with 
impulses from the hypothalamus overshadowing peripheral responses. Whatever, the mechanisms for 
this discrepancy between microvascular function and CVD risk factors, in particular lipids, the link 
between CVD risk factors and outcomes is of course far better established and thus the results more 
informative about future risk.  
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CONCLUSIONS 
The present study demonstrated a difference in the peripheral vascular reactivity of postmenopausal 
women who flush when compared with postmenopausal women who do not flush, and an adverse 
cardiovascular risk profile in this group of flushing women.  Our results suggest a need for larger 
studies to examine the CVD risk profile of women with history of severe flushing.  
Limitations 
These were all lean, Caucasian women; therefore care must be taken when extrapolating these results 
to the general population. 
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FIGURES  
 
 
Figure 2: Dose Response Curves 
Log perfusion change from baseline in perfusion (flux) units with increasing charge for acetylcholine 
and sodium nitroprusside in control women compared with flushing women.  P<0.001 and P=0.001 
respectively.  Data are mean ± SEM. 
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Figure 3: Dose Response Curve 
Log endothelial response (difference between endothelium dependent and independent responses).  
P=0.17.  Data are mean ± SEM. 
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TABLES 
 Flush Control P 
n 29 13  
Age 56 (53-61) 54 (52-57) 0.25 
Years since last 
menstrual period (LMP) 
8 (1-12) 5 (1-6) 0.15 
Smoking 0 0 - 
Body Mass Index (BMI) 25.1 (24.3-28.1) 23.0 (20.9-31.9) 0.28 
Parity 2 (0-3) 2 (2-3) 0.74 
Table 1 Demographic characteristics of study subjects 
Data are median (interquartile range).  Statistical analysis was performed using the Mann-Whitney U 
test.  All women are non-smokers and not known to be hypertensive (see Figure 2.)  
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 FLUSHING CONTROL P Adjusted P 
 
R-Sq 
(%) 
Cholesterol 
(mmol/l) 
5.77 
(5.01; 6.35) 
5.93 
(5.05; 6.57) 
0.91 0.97 6.86 
Triglyceride 
(mmol/l) 
1.17 
(0.82; 1.73) 
1.09 
(0.82; 1.53) 
0.83 0.97 11.33 
Low Density 
Lipoprotein 
(LDL)-cholesterol 
(mmol/l) 
3.51 
(2.92; 4.42) 
3.17 
(2.63; 4.30) 
0.29 0.29 14.14 
High Density 
Lipoprotein 
(HDL)-cholesterol 
(mmol/l)  
1.46 
(1.21; 1.76) 
1.84 
(1.51; 2.10) 
0.01 0.01 40.17 
Total Cholesterol 
to HDL-
Cholesterol ratio  
3.77 
(3.08; 4.74) 
2.98 
(2.59; 3.73) 
0.02 0.04 26.33 
Apolipoprotein 
A1 (mg/dl) 
155.30 
(146.15; 170.65) 
194.80 
(172.40; 200.30) 
<0.001 <0.001 94.81 
Apolipoprotein B 
(mg/dl) 
78.30 
(71.00; 104.65) 
80.40 
(62.95; 100.50) 
0.23 0.29 11.01 
      
*Systolic Blood 
Pressure  
126.07 ± 2.67 
 
120.25 ± 4.29 0.25   
*Diastolic Blood 
Pressure 
70.48 ± 2.11 
 
72.66 ± 2.34 0.61   
      
Insulin (mu/l) 5.69 
(3.48; 9.16) 
6.17 
(5.27; 8.68) 
0.59 0.67 22.99 
Glucose (mmol/l) 5.30 
(5.10; 5.60) 
5.60 
(5.25; 5.85) 
0.68 0.69 29.14 
Adiponectin 
(mg/ml) 
11.6  
(8.6; 15.1) 
11.7  
(9.7; 14.7) 
0.38 0.48 11.51 
C-Reactive 
Protein (CRP) 
(mg/l) 
1.70 
(0.64; 5.84) 
0.90 
(0.35; 1.42) 
0.07 0.18 19.7 
Inter-Cellular 
Adhesion 
Molecule 1(ICAM-
1) (ng/ml) 
243 
(202; 263) 
187 
(164; 228) 
0.02 0.05 18.87 
 
Table 2 CVD risk factors. 
Data are median (interquartile range).  Statistical analysis was performed using students t-test on log 
transformed data.  *Data are median ± SD 
Adjusted P calculated using general linear model to adjust for BMI, Age, Years since last menstrual 
period (LMP) and Parity. 
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